Maria Teresa Arevalo

US Patent:

20130189275, Jul 25, 2013

Filed:

Jun 3, 2011

Appl. No.:

13/701710

Inventors:

Maria T. Arevalo - Rochester NY, US
Patricia J. Simpson-Haidaris - Rochester NY, US
Xia Jin - Fairport NY, US
Huiyan Chen - Fairport NY, US
Matthew H. Quinn - Rochester NY, US

Assignee:

UNIVERSITY OF ROCHESTER - Rochester NY

International Classification:

A61K 39/42
A61K 31/713
A61K 38/17
A61K 31/727

US Classification:

4241471, 4241591, 514 56, 514 44 A, 514 37

Abstract:

The present invention relates to a method of interfering with dengue infection comprising interfering with dengue virus binding to a syndecan present on a cell targeted by dengue virus. The present invention further relates to treating a patient for dengue virus infection comprising administering to a patient, either having a dengue infection or a patient exposed to dengue infection, an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus. The present invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier, and an effective amount of an agent that interferes with dengue virus binding to a syndecan on a surface of a cell targeted by dengue virus.

US Patent:

20180112223, Apr 26, 2018

Filed:

Dec 12, 2017

Appl. No.:

15/838556

Inventors:

- Lubbock TX, US
Maria T. Arevalo - Athens GA, US

International Classification:

C12N 15/113
C07K 16/28

Abstract:

The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.

US Patent:

20170253636, Sep 7, 2017

Filed:

Mar 1, 2017

Appl. No.:

15/446315

Inventors:

- Lubbock TX, US
Maria T. Arevalo - Athens GA, US
Junwei Li - El Paso TX, US

International Classification:

C07K 14/005
G01N 33/50
A61K 39/145

Abstract:

The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains.

US Patent:

20160145627, May 26, 2016

Filed:

Jun 12, 2014

Appl. No.:

14/898179

Inventors:

- Lubbock TX, US
Maria T. Arevalo - El Paso TX, US

International Classification:

C12N 15/113
C07K 16/28

Abstract:

The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.